Hayano Azusa, Komohara Yoshihiro, Takashima Yasuo, Takeya Hiroto, Homma Jumpei, Fukai Junya, Iwadate Yasuo, Kajiwara Koji, Ishizawa Shin, Hondoh Hiroaki, Yamanaka Ryuya
Laboratory of Molecular Target Therapy for Cancer, Graduate School for Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
Anticancer Res. 2017 Oct;37(10):5655-5666. doi: 10.21873/anticanres.12001.
BACKGROUND/AIM: Programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) have been shown to predict response to PD-L1/PD-1-targeted therapy. We analyzed PD-L1 expression in primary central nervous system lymphomas (PCNSLs).
PD-L1 protein and mRNA expression were evaluated in 64 PCNSL tissue samples. IFN-γ, IL-10, CD4, and CD8 mRNA expression was also evaluated.
PD-L1 protein was detected in tumor cells in 2 (4.1%) cases and in tumor microenvironments in 25 (52%) cases. PD-L1 mRNA positively correlated with IFN-γ (p=0.0024) and CD4 (p=0.0005) mRNA expression. IFN-γ mRNA positively correlated with CD8 mRNA expression (p=0.0001). Furthermore, tumor cell PD-L1 expression correlated positively with overall survival (p=0.0177), whereas microenvironmental PD-L1 expression exhibited an insignificant negative trend with overall survival (p=0.188).
PD-L1 was expressed on both tumor and/or tumor-infiltrating immune cells in PCNSL. The biological roles of this marker warrant further investigation.
背景/目的：程序性细胞死亡配体1（PD-L1）/程序性细胞死亡蛋白1（PD-1）已被证明可预测对PD-L1/PD-1靶向治疗的反应。我们分析了原发性中枢神经系统淋巴瘤（PCNSL）中PD-L1的表达情况。
对64例PCNSL组织样本中的PD-L1蛋白和mRNA表达进行评估。同时也评估了IFN-γ、IL-10、CD4和CD8的mRNA表达。
在2例（4.1%）病例的肿瘤细胞以及25例（52%）病例的肿瘤微环境中检测到PD-L1蛋白。PD-L1 mRNA与IFN-γ（p=0.0024）和CD4（p=0.0005）的mRNA表达呈正相关。IFN-γ mRNA与CD8 mRNA表达呈正相关（p=0.0001）。此外，肿瘤细胞PD-L1表达与总生存期呈正相关（p=0.0177），而微环境中PD-L1表达与总生存期呈不显著的负向趋势（p=0.188）。
PD-L1在PCNSL的肿瘤细胞和/或肿瘤浸润免疫细胞上均有表达。该标志物的生物学作用值得进一步研究。
